The approval was supported by data from 2 randomized, double-blind, vehicle-controlled trials that included 736 patients aged 12 years and older with mild to severe plaque psoriasis of the scalp and ...

The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque ...

Stull said that a number of prescription treatments exist for topical psoriasis, such as steroids and injectable therapies, ...

The 0.3% foam formulation of roflumilast was previously approved for the treatment of seborrheic dermatitis in adults and ...

Topical roflumilast 0.3% cream has been approved by the FDA to treat plaque psoriasis in patients 12 years and older since ...

The FDA approved a supplemental new drug application for roflumilast topical foam 0.3% for the treatment of plaque psoriasis ...

Plaque psoriasis is characterized by raised ... Scalp psoriasis shows up as itchy, scaly patches on the scalp that may bleed if you try to remove them. About half of people who have psoriasis ...

flaky skin on your scalp. Dandruff typically appears as general flaking, but psoriasis develops from a clearly defined plaque (thick patch of skin). Psoriasis plaques can be white or grey and turn ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Once-daily roflumilast foam, 0.3% (Zoryve) significantly improved scalp and body symptoms of plaque psoriasis in a phase III trial. Improvements in scalp itch were also greater for patients ...

Get Instant Summarized Text (Gist) The FDA has approved Zoryve (roflumilast) 0.3% topical foam for once-daily treatment of plaque psoriasis on the scalp and body in patients aged 12 and older ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp and ...